This is a routine passive disclosure by a large index fund manager. No change in investment thesis. Monitor future 13G amendments for any material increase or a conversion to 13D, which would signal a shift to activist intent.
CATX drugs
CATX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $0.7864entry
- T+1 · 6d ago +4.93%α +3.62% · $0.8252
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing beneficial ownership of 2,026,991 shares of Perspective Therapeutics, representing 1.8% of common stock as of September 30, 2026. The filing is a routine passive stake disclosure by a large index fund manager, with no activist intent. The stake is small relative to the company's $96M market cap and consistent with State Street's role as a top institutional holder.
Key Financial Metrics
Key Facts
- State Street Corp filed Schedule 13G for Perspective Therapeutics (CATX) on November 10, 2026
- Beneficial ownership: 2,026,991 shares of common stock, representing 1.8% of shares outstanding
- Sole voting power: 0 shares; shared voting power: 0 shares; sole dispositive power: 1,922,605 shares; shared dispositive power: 2,026,991 shares
- Filing certifies passive intent under Rule 13d-1(b), no control or influence purpose
- State Street is a large custodial bank and index fund manager, not an activist investor
- Prior 13G filings by Millennium Management (hedge fund) were also passive, but this filing is by a different filer
Financial Impact
Stake valued at approximately $1.7M based on $96M market cap and 1.8% ownership; no transaction disclosed
Risk Factors
- No material risks identified from this filing; the stake is small and passive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000703 |
| Document: 0000093751-26-000703-index.html | 0000093751-26-000703 |
| Document: 0000093751-26-000703.txt | 0000093751-26-000703 |
Track record
34 reports on CATX
3 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.27% at T+5 after the Nov 5, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.9238 Now $0.9200 −0.41% settles Nov 18
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $0.9652 Now $0.9200 −4.68% settles Nov 17
- Nov 12, 20264d ago SC 13D/A Bearish 6/10 Entry $0.9431 to $0.9238 Now $0.9200 +2.45% ▲ +2.05% +0.13% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 2/10 Viewing Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 No price data
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers